Internal Medicine, Hematology & Oncology · Torrance, CA
NPI
1972591378
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
3285 Skypark Dr
Torrance, CA, 90505
Phone (310) 750-3300
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.6M
111,376 services
Medicare patients, 2024
356
Average age 75
Drug cost, 2024
$2.8M
1,000 prescriptions
Company payments, 2025
$505
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David Chan was code J1453 (injection, fosaprepitant, 1 mg), 13,650 times for 13 patients. In total David Chan billed 111,376 services in 68 codes, and Medicare paid $1.6M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-12-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1453 Injection, fosaprepitant, 1 mg | Office | 13,650 | 13 | $0.11 | $1,504 |
| J1642 Injection, heparin sodium, (heparin lock flush), per 10 units | Office | 6,500 | 17 | $0.01 | $81.01 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 1,171 | 14 | $0.27 | $314 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 793 | 14 | $0.09 | $72.63 |
| 85025 Blood Count | Office | 776 | 270 | $7.59 | $5,893 |
| 99214 Office E&M - Established | Office | 664 | 325 | $97.35 | $65K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 426 | 68 | $4.48 | $1,910 |
| M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 329 | 38 | $68.60 | $23K |
| 96367 Intravenous Infusion, Hydration | Office | 317 | 18 | $25.47 | $8,074 |
| 99215 Office E&M - Established | Office | 236 | 76 | $147.73 | $35K |
| 96413 Chemotherapy Administration | Office | 219 | 19 | $114.53 | $25K |
| 96365 Intravenous Infusion, Hydration | Office | 115 | 67 | $49.64 | $5,708 |
| 96372 Injection Administration | Office | 104 | 11 | $11.73 | $1,220 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 59 | 32 | $13.70 | $808 |
| 99213 Office E&M - Established | Office | 58 | 43 | $68.00 | $3,944 |
By year: 2022 $1.1M for 56,228 services; 2023 $1.4M for 92,606 services; 2024 $1.6M for 111,376 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 776 | 270 | $7.59 | $5,893 |
| 82565 Clinical Chemistry | 57 | 43 | $5.02 | $286 |
| 36415 Venipuncture Blood Collection | 18 | 17 | $8.65 | $156 |
Medicare prescription drug claims, 2024
In 2024, the drug David Chan prescribed most often to Medicare patients was Anastrozole, with 320 prescriptions and refills. In total David Chan wrote 1,000 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 320 | 923 | 99 | $7,096 |
| Raloxifene Hcl Generic | 97 | 287 | 41 | $4,007 |
| Letrozole Generic | 78 | 226 | 26 | $1,581 |
| Verzenio Abemaciclib | 47 | 47 | Under 11 | $718K |
| Trazodone Hcl Generic | 41 | 91 | 13 | $329 |
| Tamoxifen Citrate Generic | 34 | 102 | 11 | $575 |
| Orserdu Elacestrant Hcl | 32 | 32 | Under 11 | $715K |
| Exemestane Generic | 29 | 56 | Under 11 | $6,433 |
| Xarelto Rivaroxaban | 28 | 46 | Under 11 | $25K |
| Ibrance Palbociclib | 26 | 26 | Under 11 | $453K |
| Kisqali Ribociclib Succinate | 20 | 20 | Under 11 | $247K |
| Famotidine Generic | 18 | 24 | Under 11 | $86.4 |
| Omeprazole Generic | 17 | 43 | Under 11 | $112 |
| Olanzapine Generic | 16 | 20 | Under 11 | $213 |
| Estradiol Generic | 15 | 38 | 13 | $967 |
Brand drugs: - claims; generic drugs: 776 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David Chan $505 ($505 in general payments such as food, travel and fees) from 9 companies. The largest payer was InSightec,Inc with $147.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.